These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 2389391)

  • 1. Intraoperative investigation of von Willebrand factor structure and function in orthotopic liver transplantation. The Liver Transplantation Group.
    Monteagudo J; Reverter JC; Mateo D; Seoane R; Mazzara R; Escolar G; Pereira A; Castillo R; Visa J
    Transplant Proc; 1990 Aug; 22(4):1531-2. PubMed ID: 2389391
    [No Abstract]   [Full Text] [Related]  

  • 2. Alterations of von Willebrand factor and ristocetin cofactor activity during atrial fibrillation.
    Kalyoncu U; Dizdar O; Erkan Duman A; Karadag O; Tufan A; Yucel O; Tayfur O; Sen D; Ulger Z; Kepez A; Kocabas U; Haznedaroglu I
    Clin Appl Thromb Hemost; 2009 Feb; 15(1):103-8. PubMed ID: 18160605
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Values of soluble thrombomodulin and von Willebrand factor judging reject reaction in liver transplantation].
    Wen CG; Luo SK; He XS; Li J; Liu M; Zou WY; Peng AH
    Zhonghua Gan Zang Bing Za Zhi; 2003 May; 11(5):295-7. PubMed ID: 12773246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The expression of von Willebrand factor, soluble thrombomodulin, and soluble p-selectin during orthotopic liver transplantation.
    Wang YI; Li G; Zhang Y; Gao W; Yao Z
    Transplant Proc; 2007; 39(1):172-5. PubMed ID: 17275499
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive value of von Willebrand factor to ristocetin cofactor ratio and thrombin-antithrombin complex levels for hepatic vessel thrombosis and graft rejection after liver transplantation.
    Jennings I; Calne RY; Baglin TP
    Transplantation; 1994 Apr; 57(7):1046-51. PubMed ID: 8165701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transfusion requirements are correlated with the degree of proteolysis of von Willebrand factor during orthotopic liver transplantation.
    Lattuada A; Mannucci PM; Chen C; Legnani C; Palareti G
    Thromb Haemost; 1997 Aug; 78(2):813-9. PubMed ID: 9268177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative and qualitative analysis of platelet GPIb and von Willebrand factor in liver cirrhosis.
    Beer JH; Clerici N; Baillod P; von Felten A; Schlappritzi E; Büchi L
    Thromb Haemost; 1995 Apr; 73(4):601-9. PubMed ID: 7495066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dominant von Willebrand disease type 2M and 2U are variable expressions of one distinct disease entity caused by loss-of-function mutations in the A1 domain of the von Willebrand factor gene.
    Gadisseur A; van der Planken M; Schroyens W; Berneman Z; Michiels JJ
    Acta Haematol; 2009; 121(2-3):145-53. PubMed ID: 19506361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. von Willebrand factor: its function and its measurement in the laboratory.
    Fleming TG
    Br J Biomed Sci; 1995 Mar; 52(1):50-7. PubMed ID: 7549606
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of continuous infusion of a combined factor VIII-von Willebrand factor (vWF) concentrate (Haemate-P) in patients with von Willebrand disease.
    Lubetsky A; Schulman S; Varon D; Martinowitz U; Kenet G; Gitel S; Inbal A
    Thromb Haemost; 1999 Feb; 81(2):229-33. PubMed ID: 10063997
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new automated screening assay for the diagnosis of von Willebrand disease.
    Salem RO; Van Cott EM
    Am J Clin Pathol; 2007 May; 127(5):730-5. PubMed ID: 17439831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Measurement of von Willebrand factor binding to a recombinant fragment of glycoprotein Ibalpha in an enzyme-linked immunosorbent assay-based method: performances in patients with type 2B von Willebrand disease.
    Caron C; Hilbert L; Vanhoorelbeke K; Deckmyn H; Goudemand J; Mazurier C
    Br J Haematol; 2006 Jun; 133(6):655-63. PubMed ID: 16704443
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of the factor VIII/von Willebrand factor concentrate, haemate-P/humate-P: ristocetin cofactor unit dosing in patients with von Willebrand disease.
    Lillicrap D; Poon MC; Walker I; Xie F; Schwartz BA;
    Thromb Haemost; 2002 Feb; 87(2):224-30. PubMed ID: 11858481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma thrombomodulin in orthotopic liver transplantation.
    Boutiere B; Arnoux D; Boffa MC; Samson D; Le Treut YP; Sampol J
    Transplantation; 1994 Dec; 58(12):1352-5. PubMed ID: 7809928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative study on collagen-binding enzyme-linked immunosorbent assay and ristocetin cofactor activity assays for detection of functional activity of von Willebrand factor.
    Turecek PL; Siekmann J; Schwarz HP
    Semin Thromb Hemost; 2002 Apr; 28(2):149-60. PubMed ID: 11992238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of intraoperative blood transfusion on rejection and survival after orthotopic liver transplantation.
    Palomo JC; Jiménez C; Moreno E; García MA; Bercedo J; Loinaz C; Palma F; Ibañez J; Corral MA
    Transplant Proc; 1995 Aug; 27(4):2326-7. PubMed ID: 7652829
    [No Abstract]   [Full Text] [Related]  

  • 17. Effect of ABO blood group on the collagen-binding assay for von Willebrand factor.
    Haley E; Babar N; Ritter C; Downes KA; Green D; Shurin S; Sarode R
    Am J Hematol; 2002 Nov; 71(3):229-31. PubMed ID: 12410584
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Biological diagnosis of Willebrand disease].
    Siguret V; Ribba AS; Meyer D
    Ann Biol Clin (Paris); 1997; 55(6):601-6. PubMed ID: 9499922
    [No Abstract]   [Full Text] [Related]  

  • 19. Platelet dysfunction in outpatients with left ventricular assist devices.
    Steinlechner B; Dworschak M; Birkenberg B; Duris M; Zeidler P; Fischer H; Milosevic L; Wieselthaler G; Wolner E; Quehenberger P; Jilma B
    Ann Thorac Surg; 2009 Jan; 87(1):131-7. PubMed ID: 19101285
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is the activated partial thromboplastin time suitable to screen for von Willebrand factor deficiencies?
    Lippi G; Franchini M; Poli G; Salvagno GL; Montagnana M; Guidi GC
    Blood Coagul Fibrinolysis; 2007 Jun; 18(4):361-4. PubMed ID: 17473578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.